Electra Therapeutics is a clinical-stage biopharmaceutical company developing precision antibody therapies for immune-mediated diseases and cancer. The company targets signal regulatory proteins (SIRP) to selectively deplete disease-driving activated immune cells while preserving healthy immune function. Electra has two clinical-stage drug candidates. Its lead candidate, ipsoprubart, is a pan-SIRP monoclonal antibody in a Phase 2/3 registrational trial for secondary hemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory syndrome, and in Phase 1 trials for relapsed and refractory T cell and NK cell malignancies. Its second candidate, ELA822, is a SIRPg-specific antibody in Phase 1 development for chronic T cell-mediated inflammatory diseases, including giant cell arteritis and graft-versus-host disease. Electra is pre-revenue and has no approved commercial products. The company focuses on clinical R&D to advance its candidates through clinical trials and toward regulatory approval. If approved, Electra plans to commercialize its products directly in the U.S. through an internal sales force targeting hematologist-oncologists and academic medical centers, while pursuing partnerships for international distribution.